Abstract
Dementia poses an ever-growing burden to health care and social services as life expectancies have grown across the world and populations age. The most common forms of dementia are Alzheimer’s disease (AD), vascular dementia, frontotemporal dementia (FTD), and Lewy body dementia, which includes Parkinson’s disease (PD) dementia and dementia with Lewy bodies (DLB). Genomic studies over the past 3 decades have identified variants in genes regulating lipid transporters and endosomal processes as major risk determinants for AD, with the most significant being inheritance of the ε4 allele of the APOE gene, encoding apolipoprotein E. A recent surge in research on lipid handling and metabolism in glia and neurons has established defective lipid clearance from endolysosomes as a central driver of AD pathogenesis. The most prevalent genetic risk factors for DLB are the APOE ε4 allele, and heterozygous loss of function mutations in the GBA gene, encoding the lysosomal catabolic enzyme glucocerebrosidase; whilst heterozygous mutations in the GRN gene, required for lysosomal catabolism of sphingolipids, are responsible for a significant proportion of FTD cases. Homozygous mutations in the GBA or GRN genes produce the lysosomal storage diseases Gaucher disease and neuronal ceroid lipofuscinosis. Research from mouse and cell culture models, and neuropathological evidence from lysosomal storage diseases, has established that impaired cholesterol or sphingolipid catabolism is sufficient to produce the pathological hallmarks of dementia, indicating that defective lipid catabolism is a common mechanism in the etiology of dementia.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
Data Availability
Not applicable.
Code Availability
Not applicable.
References
Abe-Dohmae, S., Ikeda, Y., Matsuo, M., Hayashi, M., Okuhira, K.-I., Ueda, K., et al. (2004). Human ABCA7 supports apolipoprotein-mediated release of cellular cholesterol and phospholipid to generate high density lipoprotein. Journal of Biological Chemistry, 279(1), 604–611. https://doi.org/10.1074/jbc.M309888200.
Afghah, Z., Chen, X., & Geiger, J. D. (2020). Role of endolysosomes and inter-organellar signaling in brain disease. Neurobiology of Disease, 134, 104670. https://doi.org/10.1016/j.nbd.2019.104670.
Ahmed, Z., Mackenzie, I. R., Hutton, M. L., & Dickson, D. W. (2007). Progranulin in frontotemporal lobar degeneration and neuroinflammation. Journal of Neuroinflammation, 4, 7. https://doi.org/10.1186/1742-2094-4-7.
Almeida, S., Zhou, L., & Gao, F. B. (2011). Progranulin, a glycoprotein deficient in frontotemporal dementia, is a novel substrate of several protein disulfide isomerase family proteins. PLoS One, 6(10), e26454. https://doi.org/10.1371/journal.pone.0026454.
Almeida, M. R., Macario, M. C., Ramos, L., Baldeiras, I., Ribeiro, M. H., & Santana, I. (2016). Portuguese family with the co-occurrence of frontotemporal lobar degeneration and neuronal ceroid lipofuscinosis phenotypes due to progranulin gene mutation. Neurobiology of Aging, 41, 200 e201–200 e205. https://doi.org/10.1016/j.neurobiolaging.2016.02.019.
Alzheimer’s_Association. (2019). 2019 Alzheimer’s disease facts and figures. Alzheimer’s & Dementia, 15, 321–387.
Arias-Vásquez, A., Isaacs, A., Aulchenko, Y. S., Hofman, A., Oostra, B. A., Breteler, M., et al. (2007). The cholesteryl ester transfer protein (CETP) gene and the risk of Alzheimer’s disease. Neurogenetics, 8(3), 189–193. https://doi.org/10.1007/s10048-007-0089-x.
Astarita, G., Jung, K.-M., Vasilevko, V., DiPatrizio, N. V., Martin, S. K., Cribbs, D. H., et al. (2011). Elevated stearoyl-CoA desaturase in brains of patients with Alzheimer’s disease. PLoS One, 6(10), e24777. https://doi.org/10.1371/journal.pone.0024777.
Atagi, Y., Liu, C.-C., Painter, M. M., Chen, X.-F., Verbeeck, C., Zheng, H., et al. (2015). Apolipoprotein E is a ligand for triggering receptor expressed on myeloid cells 2 (TREM2). The Journal of Biological Chemistry, 290(43), 26043–26050. https://doi.org/10.1074/jbc.M115.679043.
Auer, I. A., Schmidt, M. L., Lee, V. M. Y., Curry, B., Suzuki, K., Shin, R. W., et al. (1995). Paired helical filament tau (PHFtau) in Niemann-Pick type C disease is similar to PHFtau in Alzheimer’s disease. Acta Neuropathologica, 90(6), 547–551. https://doi.org/10.1007/BF00318566.
Ayciriex, S., Djelti, F., Alves, S., Regazzetti, A., Gaudin, M., Varin, J., et al. (2017). Neuronal cholesterol accumulation induced by Cyp46a1 down-regulation in mouse hippocampus disrupts brain lipid homeostasis. Frontiers in Molecular Neuroscience. https://doi.org/10.3389/fnmol.2017.00211.
Bailey, A. P., Koster, G., Guillermier, C., Hirst, E. M., MacRae, J. I., Lechene, C. P., et al. (2015). Antioxidant role for lipid droplets in a stem cell niche of Drosophila. Cell, 163(2), 340–353. https://doi.org/10.1016/j.cell.2015.09.020.
Baker, M., Mackenzie, I. R., Pickering-Brown, S. M., Gass, J., Rademakers, R., Lindholm, C., et al. (2006). Mutations in progranulin cause tau-negative frontotemporal dementia linked to chromosome 17. Nature, 442(7105), 916–919. https://doi.org/10.1038/nature05016.
Bales, K. R., Verina, T., Cummins, D. J., Du, Y., Dodel, R. C., Saura, J., et al. (1999). Apolipoprotein E is essential for amyloid deposition in the APPV717F transgenic mouse model of Alzheimer’s disease. Proceedings of the National Academy of Sciences of the United States of America, 96(26), 15233–15238.
Bandaru, V. V., Troncoso, J., Wheeler, D., Pletnikova, O., Wang, J., Conant, K., et al. (2009). ApoE4 disrupts sterol and sphingolipid metabolism in Alzheimer’s but not normal brain. Neurobiology of Aging, 30(4), 591–599. https://doi.org/10.1016/j.neurobiolaging.2007.07.024.
Bang, O. Y., Kwak, Y. T., Joo, I. S., & Huh, K. (2003). Important link between dementia subtype and apolipoprotein E: A meta-analysis. Yonsei Medical Journal, 44(3), 401–413. https://doi.org/10.3349/ymj.2003.44.3.401.
Beel, A. J., Mobley, C. K., Kim, H. J., Tian, F., Hadziselimovic, A., Jap, B., et al. (2008). Structural studies of the transmembrane C-terminal domain of the amyloid precursor protein (APP): Does APP function as a cholesterol sensor? Biochemistry, 47(36), 9428–9446. https://doi.org/10.1021/bi800993c.
Belinson, H., & Michaelson, D. M. (2009). ApoE4-dependent Aβ-mediated neurodegeneration is associated with inflammatory activation in the hippocampus but not the septum. Journal of Neural Transmission, 116(11), 1427–1434. https://doi.org/10.1007/s00702-009-0218-9.
Berlau, D. J., Corrada, M. M., Head, E., & Kawas, C. H. (2009). APOE epsilon2 is associated with intact cognition but increased Alzheimer pathology in the oldest old. Neurology, 72(9), 829–834. https://doi.org/10.1212/01.wnl.0000343853.00346.a4.
Beutler, E. (2006). Gaucher disease: Multiple lessons from a single gene disorder. Acta Paediatrica Supplement, 95(451), 103–109.
Bhandari, V., Palfree, R. G., & Bateman, A. (1992). Isolation and sequence of the granulin precursor cDNA from human bone marrow reveals tandem cysteine-rich granulin domains. Proceedings of the National Academy of Sciences of the United States of America, 89(5), 1715–1719. https://doi.org/10.1073/pnas.89.5.1715.
Blauwendraat, C., Wilke, C., Simón-Sánchez, J., Jansen, I. E., Reifschneider, A., Capell, A., et al. (2018). The wide genetic landscape of clinical frontotemporal dementia: Systematic combined sequencing of 121 consecutive subjects. Genetics in Medicine, 20(2), 240–249. https://doi.org/10.1038/gim.2017.102.
Blauwendraat, C., Nalls, M. A., & Singleton, A. B. (2020). The genetic architecture of Parkinson’s disease. The Lancet Neurology, 19(2), 170–178. https://doi.org/10.1016/S1474-4422(19)30287-X.
Boehm-Cagan, A., & Michaelson, D. M. (2014). Reversal of apoE4-driven brain pathology and behavioral deficits by bexarotene. The Journal of Neuroscience: The Official Journal of the Society for Neuroscience, 34(21), 7293–7301. https://doi.org/10.1523/JNEUROSCI.5198-13.2014.
Boehm-Cagan, A., Bar, R., Liraz, O., Bielicki, J. K., Johansson, J. O., & Michaelson, D. M. (2016). ABCA1 agonist reverses the ApoE4-driven cognitive and brain pathologies. Journal of Alzheimer’s Disease: JAD, 54(3), 1219–1233. https://doi.org/10.3233/JAD-160467.
Boland, B., Smith, D. A., Mooney, D., Jung, S. S., Walsh, D. M., & Platt, F. M. (2010). Macroautophagy is not directly involved in the metabolism of amyloid precursor protein. The Journal of Biological Chemistry, 285(48), 37415–37426. https://doi.org/10.1074/jbc.M110.186411.
Boyles, J. K., Pitas, R. E., Wilson, E., Mahley, R. W., & Taylor, J. M. (1985). Apolipoprotein E associated with astrocytic glia of the central nervous system and with nonmyelinating glia of the peripheral nervous system. The Journal of Clinical Investigation, 76(4), 1501–1513. https://doi.org/10.1172/JCI112130.
Braak, H., & Braak, E. (1991). Neuropathological stageing of Alzheimer-related changes. Acta Neuropathologica, 82(4), 239–259.
Bras, J., Guerreiro, R., Darwent, L., Parkkinen, L., Ansorge, O., Escott-Price, V., et al. (2014). Genetic analysis implicates APOE, SNCA and suggests lysosomal dysfunction in the etiology of dementia with Lewy bodies. Human Molecular Genetics, 23(23), 6139–6146. https://doi.org/10.1093/hmg/ddu334.
Burkhardt, J. K., Huttler, S., Klein, A., Mobius, W., Habermann, A., Griffiths, G., et al. (1997). Accumulation of sphingolipids in SAP-precursor (prosaposin)-deficient fibroblasts occurs as intralysosomal membrane structures and can be completely reversed by treatment with human SAP-precursor. European Journal of Cell Biology, 73(1), 10–18.
Cantoni, C., Bollman, B., Licastro, D., Xie, M., Mikesell, R., Schmidt, R., et al. (2015). TREM2 regulates microglial cell activation in response to demyelination in vivo. Acta Neuropathologica, 129(3), 429–447. https://doi.org/10.1007/s00401-015-1388-1.
Caselli, R. J., Dueck, A. C., Osborne, D., Sabbagh, M. N., Connor, D. J., Ahern, G. L., et al. (2009). Longitudinal modeling of age-related memory decline and the APOE epsilon4 effect. New England Journal of Medicine, 361(3), 255–263. https://doi.org/10.1056/NEJMoa0809437.
Castellani, R. J., Plascencia-Villa, G., & Perry, G. (2019). The amyloid cascade and Alzheimer’s disease therapeutics: Theory versus observation. Laboratory Investigation, 99(7), 958–970. https://doi.org/10.1038/s41374-019-0231-z.
Castellano, J. M., Kim, J., Stewart, F. R., Jiang, H., DeMattos, R. B., Patterson, B. W., et al. (2011). Human apoE isoforms differentially regulate brain amyloid-β peptide clearance. Science Translational Medicine, 3(89), 89ra57. https://doi.org/10.1126/scitranslmed.3002156.
Cataldo, A. M., Barnett, J. L., Berman, S. A., Li, J., Quarless, S., Bursztajn, S., et al. (1995). Gene expression and cellular content of cathepsin D in Alzheimer’s disease brain: Evidence for early up-regulation of the endosomal–lysosomal system. Neuron, 14(3), 671–680. https://doi.org/10.1016/0896-6273(95)90324-0.
Cataldo, A. M., Peterhoff, C. M., Troncoso, J. C., Gomez-Isla, T., Hyman, B. T., & Nixon, R. A. (2000). Endocytic pathway abnormalities precede amyloid β deposition in sporadic Alzheimer’s disease and Down syndrome. The American Journal of Pathology, 157(1), 277–286.
Cenik, B., Sephton, C. F., Kutluk Cenik, B., Herz, J., & Yu, G. (2012). Progranulin: A proteolytically processed protein at the crossroads of inflammation and neurodegeneration. Journal of Biological Chemistry, 287(39), 32298–32306. https://doi.org/10.1074/jbc.R112.399170.
Chan, R. B., Oliveira, T. G., Cortes, E. P., Honig, L. S., Duff, K. E., Small, S. A., et al. (2012). Comparative lipidomic analysis of mouse and human brain with Alzheimer disease. The Journal of Biological Chemistry, 287(4), 2678–2688. https://doi.org/10.1074/jbc.M111.274142.
Chen, S., Averett, N. T., Manelli, A., Ladu, M. J., May, W., & Ard, M. D. (2005a). Isoform-specific effects of apolipoprotein E on secretion of inflammatory mediators in adult rat microglia. Journal of Alzheimer’s Disease: JAD, 7(1), 25–35. https://doi.org/10.3233/jad-2005-7104.
Chen, W., Wang, N., & Tall, A. R. (2005b). A PEST deletion mutant of ABCA1 shows impaired internalization and defective cholesterol efflux from late endosomes. Journal of Biological Chemistry, 280(32), 29277–29281. https://doi.org/10.1074/jbc.M505566200.
Chen, Y., Durakoglugil, M. S., Xian, X., & Herz, J. (2010). ApoE4 reduces glutamate receptor function and synaptic plasticity by selectively impairing ApoE receptor recycling. Proceedings of the National Academy of Sciences of the United States of America, 107(26), 12011–12016. https://doi.org/10.1073/pnas.0914984107.
Chiasserini, D., Paciotti, S., Eusebi, P., Persichetti, E., Tasegian, A., Kurzawa-Akanbi, M., et al. (2015). Selective loss of glucocerebrosidase activity in sporadic Parkinson’s disease and dementia with Lewy bodies. Molecular Neurodegeneration, 10, 15. https://doi.org/10.1186/s13024-015-0010-2.
Chow, V. W., Mattson, M. P., Wong, P. C., & Gleichmann, M. (2010). An overview of APP processing enzymes and products. Neuromolecular Medicine, 12(1), 1–12. https://doi.org/10.1007/s12017-009-8104-z.
Christomanou, H., Chabas, A., Pampols, T., & Guardiola, A. (1989). Activator protein deficient Gaucher’s disease. A second patient with the newly identified lipid storage disorder. Klinische Wochenschrift, 67(19), 999–1003. https://doi.org/10.1007/BF01716064.
Clark, L. N., Ross, B. M., Wang, Y., Mejia-Santana, H., Harris, J., Louis, E. D., et al. (2007). Mutations in the glucocerebrosidase gene are associated with early-onset Parkinson disease. Neurology, 69(12), 1270–1277. https://doi.org/10.1212/01.wnl.0000276989.17578.02.
Conway, O. J., Carrasquillo, M. M., Wang, X., Bredenberg, J. M., Reddy, J. S., Strickland, S. L., et al. (2018). ABI3 and PLCG2 missense variants as risk factors for neurodegenerative diseases in Caucasians and African Americans. Molecular Neurodegeneration, 13(1), 53. https://doi.org/10.1186/s13024-018-0289-x.
Corder, E. H., Saunders, A. M., Strittmatter, W. J., Schmechel, D. E., Gaskell, P. C., Small, G. W., et al. (1993). Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer’s disease in late onset families. Science (New York, N.Y.), 261(5123), 921–923. https://doi.org/10.1126/science.8346443.
Corder, E. H., Saunders, A. M., Risch, N. J., Strittmatter, W. J., Schmechel, D. E., Gaskell, P. C., et al. (1994). Protective effect of apolipoprotein E type 2 allele for late onset Alzheimer disease. Nature Genetics, 7(2), 180–184. https://doi.org/10.1038/ng0694-180.
Cossec, J.-C., Simon, A., Marquer, C., Moldrich, R. X., Leterrier, C., Rossier, J., et al. (2010). Clathrin-dependent APP endocytosis and Aβ secretion are highly sensitive to the level of plasma membrane cholesterol. Biochimica et Biophysica Acta (BBA)-Molecular and Cell Biology of Lipids, 1801(8), 846–852. https://doi.org/10.1016/j.bbalip.2010.05.010.
Couttas, T. A., Kain, N., Daniels, B., Lim, X. Y., Shepherd, C., Kril, J., et al. (2014). Loss of the neuroprotective factor Sphingosine 1-phosphate early in Alzheimer’s disease pathogenesis. Acta Neuropathologica Communications, 2, 9. https://doi.org/10.1186/2051-5960-2-9.
Couttas, T. A., Kain, N., Tran, C., Chatterton, Z., Kwok, J. B., & Don, A. S. (2018). Age-dependent changes to sphingolipid balance in the human hippocampus are gender-specific and may sensitize to neurodegeneration. Journal of Alzheimer’s Disease: JAD, 63(2), 503–514. https://doi.org/10.3233/JAD-171054.
Coyle-Gilchrist, I. T., Dick, K. M., Patterson, K., Vazquez Rodriquez, P., Wehmann, E., Wilcox, A., et al. (2016). Prevalence, characteristics, and survival of frontotemporal lobar degeneration syndromes. Neurology, 86(18), 1736–1743. https://doi.org/10.1212/WNL.0000000000002638.
Cruchaga, C., Karch, C. M., Jin, S. C., Benitez, B. A., Cai, Y., Guerreiro, R., et al. (2014). Rare coding variants in phospholipase D3 (PLD3) confer risk for Alzheimer’s disease. Nature, 505(7484), 550–554. https://doi.org/10.1038/nature12825.
Cruts, M., Gijselinck, I., van der Zee, J., Engelborghs, S., Wils, H., Pirici, D., et al. (2006). Null mutations in progranulin cause ubiquitin-positive frontotemporal dementia linked to chromosome 17q21. Nature, 442(7105), 920–924. https://doi.org/10.1038/nature05017.
Cuervo, A. M., & Dice, J. F. (1998). How do intracellular proteolytic systems change with age? Frontiers in Bioscience, 3, d25–d43. https://doi.org/10.2741/a264.
Cuervo, A. M., & Dice, J. F. (2000). When lysosomes get old. Experimental Gerontology, 35(2), 119–131. https://doi.org/10.1016/s0531-5565(00)00075-9.
Cummings, J., Lee, G., Ritter, A., Sabbagh, M., & Zhong, K. (2020). Alzheimer’s disease drug development pipeline: 2020. Alzheimers Dement (N Y), 6(1), e12050. https://doi.org/10.1002/trc2.12050.
Davis, A. A., Inman, C. E., Wargel, Z. M., Dube, U., Freeberg, B. M., Galluppi, A., et al. (2020). APOE genotype regulates pathology and disease progression in synucleinopathy. Science Translational Medicine, 12(529), eaay3069. https://doi.org/10.1126/scitranslmed.aay3069.
de Chaves, E. I., Rusiñol, A. E., Vance, D. E., Campenot, R. B., & Vance, J. E. (1997). Role of lipoproteins in the delivery of lipids to axons during axonal regeneration. The Journal of Biological Chemistry, 272(49), 30766–30773. https://doi.org/10.1074/jbc.272.49.30766.
Dickson, D. W., Heckman, M. G., Murray, M. E., Soto, A. I., Walton, R. L., Diehl, N. N., et al. (2018). APOE ε4 is associated with severity of Lewy body pathology independent of Alzheimer pathology. Neurology, 91(12), e1182–e1195. https://doi.org/10.1212/WNL.0000000000006212.
Dik, M. G., Jonker, C., Bouter, L. M., Geerlings, M. I., van Kamp, G. J., & Deeg, D. J. (2000). APOE-epsilon4 is associated with memory decline in cognitively impaired elderly. Neurology, 54(7), 1492–1497. https://doi.org/10.1212/wnl.54.7.1492.
Djelti, F., Braudeau, J., Hudry, E., Dhenain, M., Varin, J., Bièche, I., et al. (2015). CYP46A1 inhibition, brain cholesterol accumulation and neurodegeneration pave the way for Alzheimer’s disease. Brain, 138(8), 2383–2398. https://doi.org/10.1093/brain/awv166.
Du, W., Tan, J., Xu, W., Chen, J., & Wang, L. (2016). Association between clusterin gene polymorphism rs11136000 and late-onset Alzheimer’ disease susceptibility: A review and meta-analysis of case-control studies. Experimental and Therapeutic Medicine, 12(5), 2915–2927. https://doi.org/10.3892/etm.2016.3734.
Ehehalt, R., Keller, P., Haass, C., Thiele, C., & Simons, K. (2003). Amyloidogenic processing of the Alzheimer beta-amyloid precursor protein depends on lipid rafts. The Journal of Cell Biology, 160(1), 113–123. https://doi.org/10.1083/jcb.200207113.
Emre, M., Aarsland, D., Brown, R., Burn, D. J., Duyckaerts, C., Mizuno, Y., et al. (2007). Clinical diagnostic criteria for dementia associated with Parkinson’s disease. Movement Disorders, 22(12), 1689–1707. https://doi.org/10.1002/mds.21507 (quiz 1837).
Evers, B. M., Rodriguez-Navas, C., Tesla, R. J., Prange-Kiel, J., Wasser, C. R., Yoo, K. S., et al. (2017). Lipidomic and transcriptomic basis of lysosomal dysfunction in progranulin deficiency. Cell Reports, 20(11), 2565–2574. https://doi.org/10.1016/j.celrep.2017.08.056.
Farrer, L. A., Cupples, L. A., Haines, J. L., Hyman, B., Kukull, W. A., Mayeux, R., et al. (1997). Effects of age, sex, and ethnicity on the association between apolipoprotein E genotype and Alzheimer disease: A meta-analysis. JAMA, 278(16), 1349–1356. https://doi.org/10.1001/jama.1997.03550160069041.
Federoff, M., Jimenez-Rolando, B., Nalls, M. A., & Singleton, A. B. (2012). A large study reveals no association between APOE and Parkinson’s disease. Neurobiology of Disease, 46(2), 389–392. https://doi.org/10.1016/j.nbd.2012.02.002.
Floris, G., Borghero, G., Cannas, A., Di Stefano, F., Murru, M. R., Corongiu, D., et al. (2015). Clinical phenotypes and radiological findings in frontotemporal dementia related to TARDBP mutations. Journal of Neurology, 262(2), 375–384. https://doi.org/10.1007/s00415-014-7575-5.
Friedberg, J. S., Aytan, N., Cherry, J. D., Xia, W., Standring, O. J., Alvarez, V. E., et al. (2020). Associations between brain inflammatory profiles and human neuropathology are altered based on apolipoprotein E ε4 genotype. Scientific Reports, 10(1), 2924. https://doi.org/10.1038/s41598-020-59869-5.
Fritchie, K., Siintola, E., Armao, D., Lehesjoki, A. E., Marino, T., Powell, C., et al. (2009). Novel mutation and the first prenatal screening of cathepsin D deficiency (CLN10). Acta Neuropathologica, 117(2), 201–208. https://doi.org/10.1007/s00401-008-0426-7.
Gegg, M. E., Burke, D., Heales, S. J., Cooper, J. M., Hardy, J., Wood, N. W., et al. (2012). Glucocerebrosidase deficiency in substantia nigra of parkinson disease brains. Annals of Neurology, 72(3), 455–463. https://doi.org/10.1002/ana.23614.
Gegg, M. E., Sweet, L., Wang, B. H., Shihabuddin, L. S., Sardi, S. P., & Schapira, A. H. (2015). No evidence for substrate accumulation in Parkinson brains with GBA mutations. Movement Disorders, 30(8), 1085–1089. https://doi.org/10.1002/mds.26278.
Gilat-Frenkel, M., Boehm-Cagan, A., Liraz, O., Xian, X., Herz, J., & Michaelson, D. M. (2014). Involvement of the Apoer2 and Lrp1 receptors in mediating the pathological effects of ApoE4 in vivo. Current Alzheimer Research, 11(6), 549–557. https://doi.org/10.2174/1567205010666131119232444.
Ginsberg, S. D., Mufson, E. J., Counts, S. E., Wuu, J., Alldred, M. J., Nixon, R. A., et al. (2010). Regional selectivity of rab5 and rab7 protein up regulation in mild cognitive impairment and Alzheimer’s disease. Journal of Alzheimer’s Disease: JAD, 22(2), 631–639. https://doi.org/10.3233/JAD-2010-101080.
Ginsberg, S. D., Mufson, E. J., Alldred, M. J., Counts, S. E., Wuu, J., Nixon, R. A., et al. (2011). Upregulation of select rab GTPases in cholinergic basal forebrain neurons in mild cognitive impairment and Alzheimer’s disease. Journal of Chemical Neuroanatomy, 42(2), 102–110. https://doi.org/10.1016/j.jchemneu.2011.05.012.
Global_Burden_of_Disease_Dementia_Collaborators. (2019). Global, regional, and national burden of Alzheimer’s disease and other dementias, 1990–2016: A systematic analysis for the Global Burden of Disease Study 2016. The Lancet Neurologys, 18(1), 88–106. https://doi.org/10.1016/S1474-4422(18)30403-4.
Gomez-Ramos, A., Diaz-Nido, J., Smith, M. A., Perry, G., & Avila, J. (2003). Effect of the lipid peroxidation product acrolein on tau phosphorylation in neural cells. Journal of Neuroscience Research, 71(6), 863–870. https://doi.org/10.1002/jnr.10525.
Goritz, C., Mauch, D. H., & Pfrieger, F. W. (2005). Multiple mechanisms mediate cholesterol-induced synaptogenesis in a CNS neuron. Molecular and Cellular Neuroscience, 29(2), 190–201. https://doi.org/10.1016/j.mcn.2005.02.006.
Gotzl, J. K., Mori, K., Damme, M., Fellerer, K., Tahirovic, S., Kleinberger, G., et al. (2014). Common pathobiochemical hallmarks of progranulin-associated frontotemporal lobar degeneration and neuronal ceroid lipofuscinosis. Acta Neuropathologica, 127(6), 845–860. https://doi.org/10.1007/s00401-014-1262-6.
Graham, W. V., Bonito-Oliva, A., & Sakmar, T. P. (2017). Update on Alzheimer’s disease therapy and prevention strategies. Annual Review of Medicine, 68, 413–430. https://doi.org/10.1146/annurev-med-042915-103753.
Greaves, C. V., & Rohrer, J. D. (2019). An update on genetic frontotemporal dementia. Journal of Neurology, 266(8), 2075–2086. https://doi.org/10.1007/s00415-019-09363-4.
Guerreiro, R., Wojtas, A., Bras, J., Carrasquillo, M., Rogaeva, E., Majounie, E., et al. (2013). TREM2 variants in Alzheimer’s disease. The New England Journal of Medicine, 368(2), 117–127. https://doi.org/10.1056/NEJMoa1211851.
Haass, C., Koo, E. H., Mellon, A., Hung, A. Y., & Selkoe, D. J. (1992). Targeting of cell-surface beta-amyloid precursor protein to lysosomes: Alternative processing into amyloid-bearing fragments. Nature, 357(6378), 500–503. https://doi.org/10.1038/357500a0.
Han, X., Cheng, H., Fryer, J. D., Fagan, A. M., & Holtzman, D. M. (2003). Novel role for apolipoprotein E in the central nervous system. Modulation of sulfatide content. Journal of Biological Chemistry, 278(10), 8043–8051. https://doi.org/10.1074/jbc.M212340200.
Hanson, A. J., Bayer-Carter, J. L., Green, P. S., Montine, T. J., Wilkinson, C. W., Baker, L. D., et al. (2013). Effect of apolipoprotein E genotype and diet on apolipoprotein E lipidation and amyloid peptides: Randomized clinical trial. JAMA Neurology, 70(8), 972–980. https://doi.org/10.1001/jamaneurol.2013.396.
Hardy, J., Crook, R., Prihar, G., Roberts, G., Raghavan, R., & Perry, R. (1994). Senile dementia of the Lewy body type has an apolipoprotein E epsilon 4 allele frequency intermediate between controls and Alzheimer’s disease. Neuroscience Letters, 182(1), 1–2. https://doi.org/10.1016/0304-3940(94)90190-2.
Hayashi, M., Abe-Dohmae, S., Okazaki, M., Ueda, K., & Yokoyama, S. (2005). Heterogeneity of high density lipoprotein generated by ABCA1 and ABCA7. Journal of Lipid Research, 46(8), 1703–1711. https://doi.org/10.1194/jlr.M500092-JLR200.
He, Z., Ong, C. H., Halper, J., & Bateman, A. (2003). Progranulin is a mediator of the wound response. Nature Medicine, 9(2), 225–229. https://doi.org/10.1038/nm816.
He, X., Huang, Y., Li, B., Gong, C.-X., & Schuchman, E. H. (2010). Deregulation of sphingolipid metabolism in Alzheimer’s disease. Neurobiology of Aging, 31(3), 398–408. https://doi.org/10.1016/j.neurobiolaging.2008.05.010.
Heinsinger, N. M., Gachechiladze, M. A., & Rebeck, G. W. (2016). Apolipoprotein E genotype affects size of ApoE complexes in cerebrospinal fluid. Journal of Neuropathology and Experimental Neurology, 75(10), 918–924. https://doi.org/10.1093/jnen/nlw067.
Helkala, E. L., Koivisto, K., Hanninen, T., Vanhanen, M., Kervinen, K., Kuusisto, J., et al. (1995). The association of apolipoprotein E polymorphism with memory: A population based study. Neuroscience Letters, 191(3), 141–144. https://doi.org/10.1016/0304-3940(95)11575-h.
Henderson, M. X., Sedor, S., McGeary, I., Cornblath, E. J., Peng, C., Riddle, D. M., et al. (2020). Glucocerebrosidase activity modulates neuronal susceptibility to pathological alpha-synuclein insult. Neuron, 105(5), 822–836. https://doi.org/10.1016/j.neuron.2019.12.004.
Hiraiwa, M., Martin, B. M., Kishimoto, Y., Conner, G. E., Tsuji, S., & O’Brien, J. S. (1997). Lysosomal proteolysis of prosaposin, the precursor of saposins (sphingolipid activator proteins): Its mechanism and inhibition by ganglioside. Archives of Biochemistry and Biophysics, 341(1), 17–24. https://doi.org/10.1006/abbi.1997.9958.
Hirsch-Reinshagen, V., Zhou, S., Burgess, B. L., Bernier, L., McIsaac, S. A., Chan, J. Y., et al. (2004). Deficiency of ABCA1 impairs apolipoprotein E metabolism in brain. Journal of Biological Chemistry, 279(39), 41197–41207. https://doi.org/10.1074/jbc.M407962200.
Hogan, D. B., Fiest, K. M., Roberts, J. I., Maxwell, C. J., Dykeman, J., Pringsheim, T., et al. (2016a). The prevalence and incidence of dementia with Lewy bodies: A systematic review. Canadian Journal of Neurological Sciences, 43(Suppl 1), S83–S95. https://doi.org/10.1017/cjn.2016.2.
Hogan, D. B., Jette, N., Fiest, K. M., Roberts, J. I., Pearson, D., Smith, E. E., et al. (2016b). The prevalence and incidence of frontotemporal dementia: A systematic review. Canadian Journal of Neurological Sciences, 43(Suppl 1), S96–S109. https://doi.org/10.1017/cjn.2016.25.
Hollingworth, P., Harold, D., Sims, R., Gerrish, A., Lambert, J.-C., Carrasquillo, M. M., et al. (2011). Common variants at ABCA7, MS4A6A/MS4A4E, EPHA1, CD33 and CD2AP are associated with Alzheimer’s disease. Nature Genetics, 43(5), 429–435. https://doi.org/10.1038/ng.803.
Hu, F., Padukkavidana, T., Vaegter, C. B., Brady, O. A., Zheng, Y., Mackenzie, I. R., et al. (2010). Sortilin-mediated endocytosis determines levels of the frontotemporal dementia protein, progranulin. Neuron, 68(4), 654–667. https://doi.org/10.1016/j.neuron.2010.09.034.
Hu, J., Liu, C. C., Chen, X. F., Zhang, Y. W., Xu, H., & Bu, G. (2015). Opposing effects of viral mediated brain expression of apolipoprotein E2 (apoE2) and apoE4 on apoE lipidation and Abeta metabolism in apoE4-targeted replacement mice. Molecular Neurodegeneration, 10, 6. https://doi.org/10.1186/s13024-015-0001-3.
Huang, Y., & Mahley, R. W. (2014). Apolipoprotein E: Structure and function in lipid metabolism, neurobiology, and Alzheimer’s diseases. Neurobiology of Disease, 72PA, 3–12. https://doi.org/10.1016/j.nbd.2014.08.025.
Huang, M., Wang, D., Xu, Z., Xu, Y., Xu, X., Ma, Y., et al. (2015). Lack of genetic association between TREM2 and Alzheimer’s disease in East Asian population: A systematic review and meta-analysis. American Journal of Alzheimer’s Disease & Other Dementiasr, 30(6), 541–546. https://doi.org/10.1177/1533317515577128.
Hubin, E., Verghese, P. B., van Nuland, N., & Broersen, K. (2019). Apolipoprotein E associated with reconstituted high-density lipoprotein-like particles is protected from aggregation. FEBS Letters, 593(11), 1144–1153. https://doi.org/10.1002/1873-3468.13428.
Hulkova, H., Cervenkova, M., Ledvinova, J., Tochackova, M., Hrebicek, M., Poupetova, H., et al. (2001). A novel mutation in the coding region of the prosaposin gene leads to a complete deficiency of prosaposin and saposins, and is associated with a complex sphingolipidosis dominated by lactosylceramide accumulation. Human Molecular Genetics, 10(9), 927–940. https://doi.org/10.1093/hmg/10.9.927.
Hung, C. O. Y., & Livesey, F. J. (2018). Altered γ-secretase processing of APP disrupts lysosome and autophagosome function in monogenic Alzheimer’s disease. Cell Reports, 25(13), 3647-3660.e3642. https://doi.org/10.1016/j.celrep.2018.11.095.
Hyman, B. T., Phelps, C. H., Beach, T. G., Bigio, E. H., Cairns, N. J., Carrillo, M. C., et al. (2012). National Institute on Aging-Alzheimer’s Association guidelines for the neuropathologic assessment of Alzheimer’s disease. Alzheimers Dementia, 8(1), 1–13. https://doi.org/10.1016/j.jalz.2011.10.007.
Infante, R. E., Wang, M. L., Radhakrishnan, A., Kwon, H. J., Brown, M. S., & Goldstein, J. L. (2008). NPC2 facilitates bidirectional transfer of cholesterol between NPC1 and lipid bilayers, a step in cholesterol egress from lysosomes. Proceedings of the National Academy of Sciences of the United States of America, 105(40), 15287–15292. https://doi.org/10.1073/pnas.0807328105.
Ioannou, M. S., Jackson, J., Sheu, S. H., Chang, C. L., Weigel, A. V., Liu, H., et al. (2019). Neuron-astrocyte metabolic coupling protects against activity-induced fatty acid toxicity. Cell, 177(6), 1522–1535 e1514. https://doi.org/10.1016/j.cell.2019.04.001.
Ittner, A., Chua, S. W., Bertz, J., Volkerling, A., van der Hoven, J., Gladbach, A., et al. (2016). Site-specific phosphorylation of tau inhibits amyloid-beta toxicity in Alzheimer’s mice. Science, 354(6314), 904–908. https://doi.org/10.1126/science.aah6205.
Jankowsky, J. L., & Zheng, H. (2017). Practical considerations for choosing a mouse model of Alzheimer’s disease. Molecular Neurodegeneration, 12(1), 89. https://doi.org/10.1186/s13024-017-0231-7.
Jeyakumar, M., Thomas, R., Elliot-Smith, E., Smith, D. A., van der Spoel, A. C., d’Azzo, A., et al. (2003). Central nervous system inflammation is a hallmark of pathogenesis in mouse models of GM1 and GM2 gangliosidosis. Brain, 126(Pt 4), 974–987. https://doi.org/10.1093/brain/awg089.
Jiang, T., Tan, L., Chen, Q., Tan, M. S., Zhou, J. S., Zhu, X. C., et al. (2016). A rare coding variant in TREM2 increases risk for Alzheimer’s disease in Han Chinese. Neurobiology of Aging, 42(217), e211–e213. https://doi.org/10.1016/j.neurobiolaging.2016.02.023.
Jin, S. C., Carrasquillo, M. M., Benitez, B. A., Skorupa, T., Carrell, D., Patel, D., et al. (2015). TREM2 is associated with increased risk for Alzheimer’s disease in African Americans. Molecular Neurodegeneration, 10, 19. https://doi.org/10.1186/s13024-015-0016-9.
Jochemsen, H. M., Muller, M., van der Graaf, Y., & Geerlings, M. I. (2012). APOE epsilon4 differentially influences change in memory performance depending on age. The SMART-MR study. Neurobiology of Aging, 33(4), 832.e15–832.e22. https://doi.org/10.1016/j.neurobiolaging.2011.07.016.
Jones, P. B., Adams, K. W., Rozkalne, A., Spires-Jones, T. L., Hshieh, T. T., Hashimoto, T., et al. (2011). Apolipoprotein E: isoform specific differences in tertiary structure and interaction with amyloid-beta in human Alzheimer brain. PLoS One, 6(1), e14586. https://doi.org/10.1371/journal.pone.0014586.
Jonsson, T., Atwal, J. K., Steinberg, S., Snaedal, J., Jonsson, P. V., Bjornsson, S., et al. (2012). A mutation in APP protects against Alzheimer’s disease and age-related cognitive decline. Nature, 488(7409), 96–99. https://doi.org/10.1038/nature11283.
Kabashi, E., Valdmanis, P. N., Dion, P., Spiegelman, D., McConkey, B. J., Vande Velde, C., et al. (2008). TARDBP mutations in individuals with sporadic and familial amyotrophic lateral sclerosis. Nature Genetics, 40(5), 572–574. https://doi.org/10.1038/ng.132.
Kane, L. A., Lazarou, M., Fogel, A. I., Li, Y., Yamano, K., Sarraf, S. A., et al. (2014). PINK1 phosphorylates ubiquitin to activate Parkin E3 ubiquitin ligase activity. Journal of Cell Biology, 205(2), 143–153. https://doi.org/10.1083/jcb.201402104.
Kane, J. P. M., Surendranathan, A., Bentley, A., Barker, S. A. H., Taylor, J. P., Thomas, A. J., et al. (2018). Clinical prevalence of Lewy body dementia. Alzheimer’s Research & Therapy, 10(1), 19. https://doi.org/10.1186/s13195-018-0350-6.
Karch, C. M., & Goate, A. M. (2015). Alzheimer’s disease risk genes and mechanisms of disease pathogenesis. Biological Psychiatry, 77(1), 43–51. https://doi.org/10.1016/j.biopsych.2014.05.006.
Keilani, S., Lun, Y., Stevens, A. C., Williams, H. N., Sjoberg, E. R., Khanna, R., et al. (2012). Lysosomal dysfunction in a mouse model of Sandhoff disease leads to accumulation of ganglioside-bound amyloid-β peptide. The Journal of Neuroscience, 32(15), 5223–5236. https://doi.org/10.1523/JNEUROSCI.4860-11.2012.
Keren-Shaul, H., Spinrad, A., Weiner, A., Matcovitch-Natan, O., Dvir-Szternfeld, R., Ulland, T. K., et al. (2017). A unique microglia type associated with restricting development of Alzheimer’s disease. Cell, 169(7), 1276–1290.e1217. https://doi.org/10.1016/j.cell.2017.05.018.
Kim, W. S., Li, H., Ruberu, K., Chan, S., Elliott, D. A., Low, J. K., et al. (2013). Deletion of Abca7 increases cerebral amyloid-β accumulation in the J20 mouse model of Alzheimer’s disease. The Journal of Neuroscience: The Official Journal of the Society for Neuroscience, 33(10), 4387–4394. https://doi.org/10.1523/JNEUROSCI.4165-12.2013.
Klein, Z. A., Takahashi, H., Ma, M., Stagi, M., Zhou, M., Lam, T. T., et al. (2017). Loss of TMEM106B ameliorates lysosomal and frontotemporal dementia-related phenotypes in progranulin-deficient mice. Neuron, 95(2), 281–296 e286. https://doi.org/10.1016/j.neuron.2017.06.026.
Kline, A. (2012). Apolipoprotein E, amyloid-ß clearance and therapeutic opportunities in Alzheimer’s disease. Alzheimer’s Research & Therapy, 4(4), 32. https://doi.org/10.1186/alzrt135.
Konttinen, H., Cabral-da-Silva, M. E. C., Ohtonen, S., Wojciechowski, S., Shakirzyanova, A., Caligola, S., et al. (2019). PSEN1DeltaE9, APPswe, and APOE4 confer disparate phenotypes in human iPSC-derived microglia. Stem Cell Reports, 13(4), 669–683. https://doi.org/10.1016/j.stemcr.2019.08.004.
Koo, E. H., & Squazzo, S. L. (1994). Evidence that production and release of amyloid beta-protein involves the endocytic pathway. The Journal of Biological Chemistry, 269(26), 17386–17389.
Koyano, F., Okatsu, K., Kosako, H., Tamura, Y., Go, E., Kimura, M., et al. (2014). Ubiquitin is phosphorylated by PINK1 to activate parkin. Nature, 510(7503), 162–166. https://doi.org/10.1038/nature13392.
Krasemann, S., Madore, C., Cialic, R., Baufeld, C., Calcagno, N., El Fatimy, R., et al. (2017). The TREM2-APOE pathway drives the transcriptional phenotype of dysfunctional microglia in neurodegenerative diseases. Immunity, 47(3), 566–581.e569. https://doi.org/10.1016/j.immuni.2017.08.008.
Kuchar, L., Ledvinova, J., Hrebicek, M., Myskova, H., Dvorakova, L., Berna, L., et al. (2009). Prosaposin deficiency and saposin B deficiency (activator-deficient metachromatic leukodystrophy): Report on two patients detected by analysis of urinary sphingolipids and carrying novel PSAP gene mutations. American Journal of Medical Genetics Part A, 149A(4), 613–621. https://doi.org/10.1002/ajmg.a.32712.
Kurzawa-Akanbi, M., Hanson, P. S., Blain, P. G., Lett, D. J., McKeith, I. G., Chinnery, P. F., et al. (2012). Glucocerebrosidase mutations alter the endoplasmic reticulum and lysosomes in Lewy body disease. Journal of Neurochemistry, 123(2), 298–309. https://doi.org/10.1111/j.1471-4159.2012.07879.x.
Kwart, D., Gregg, A., Scheckel, C., Murphy, E. A., Paquet, D., Duffield, M., et al. (2019). A large panel of isogenic APP and PSEN1 mutant human iPSC neurons reveals shared endosomal abnormalities mediated by APP β-CTFs, not Aβ. Neuron, 104(5), 1022. https://doi.org/10.1016/j.neuron.2019.11.010.
Kwon, Y. H., Kim, J., Kim, C. S., Tu, T. H., Kim, M. S., Suk, K., et al. (2017). Hypothalamic lipid-laden astrocytes induce microglia migration and activation. FEBS Letters, 591(12), 1742–1751. https://doi.org/10.1002/1873-3468.12691.
Lambert, J. C., Ibrahim-Verbaas, C. A., Harold, D., Naj, A. C., Sims, R., Bellenguez, C., et al. (2013). Meta-analysis of 74,046 individuals identifies 11 new susceptibility loci for Alzheimer’s disease. Nature Genetics, 45(12), 1452–1458. https://doi.org/10.1038/ng.2802.
Lee, J.-H., Yu, W. H., Kumar, A., Lee, S., Mohan, P. S., Peterhoff, C. M., et al. (2010). Lysosomal proteolysis and autophagy require presenilin 1 and are disrupted by Alzheimer-related PS1 mutations. Cell, 141(7), 1146–1158. https://doi.org/10.1016/j.cell.2010.05.008.
Lee, J. S., Kanai, K., Suzuki, M., Kim, W. S., Yoo, H. S., Fu, Y., et al. (2019). Arylsulfatase A, a genetic modifier of Parkinson’s disease, is an alpha-synuclein chaperone. Brain, 142(9), 2845–2859. https://doi.org/10.1093/brain/awz205.
Lefterov, I., Wolfe, C. M., Fitz, N. F., Nam, K. N., Letronne, F., Biedrzycki, R. J., et al. (2019). APOE2 orchestrated differences in transcriptomic and lipidomic profiles of postmortem AD brain. Alzheimer’s Research & Therapy, 11(1), 113. https://doi.org/10.1186/s13195-019-0558-0.
Lei, M., Teo, J. D., Song, H., McEwen, H. P., Lee, J. Y., Couttas, T. A., et al. (2019). Sphingosine kinase 2 potentiates amyloid deposition but protects against hippocampal volume loss and demyelination in a mouse model of Alzheimer’s disease. Journal of Neuroscience, 39(48), 9645–9659. https://doi.org/10.1523/JNEUROSCI.0524-19.2019.
Lek, M., Karczewski, K. J., Minikel, E. V., Samocha, K. E., Banks, E., Fennell, T., et al. (2016). Analysis of protein-coding genetic variation in 60,706 humans. Nature, 536(7616), 285–291. https://doi.org/10.1038/nature19057.
Li, Y., Liu, L., Barger, S. W., & Griffin, W. S. T. (2003). Interleukin-1 mediates pathological effects of microglia on tau phosphorylation and on synaptophysin synthesis in cortical neurons through a p38-MAPK pathway. The Journal of Neuroscience, 23(5), 1605. https://doi.org/10.1523/JNEUROSCI.23-05-01605.2003.
Liao, Y. C., Lee, W. J., Hwang, J. P., Wang, Y. F., Tsai, C. F., Wang, P. N., et al. (2014). ABCA7 gene and the risk of Alzheimer’s disease in Han Chinese in Taiwan. Neurobiol Aging, 35(10), 2423 e2427–2423 e2413. https://doi.org/10.1016/j.neurobiolaging.2014.05.009.
Lin, Y.-T., Seo, J., Gao, F., Feldman, H. M., Wen, H.-L., Penney, J., et al. (2018). APOE4 causes widespread molecular and cellular alterations associated with Alzheimer’s disease phenotypes in human iPSC-derived brain cell types. Neuron, 98(6), 1141–1154.e1147. https://doi.org/10.1016/j.neuron.2018.05.008.
Lingwood, D., & Simons, K. (2010). Lipid rafts as a membrane-organizing principle. Science, 327(5961), 46–50. https://doi.org/10.1126/science.1174621.
Lipinski, M. M., Zheng, B., Lu, T., Yan, Z., Py, B. F., Ng, A., et al. (2010). Genome-wide analysis reveals mechanisms modulating autophagy in normal brain aging and in Alzheimer’s disease. Proceedings of the National Academy of Sciences of the United States of America, 107(32), 14164–14169. https://doi.org/10.1073/pnas.1009485107.
Lippa, C. F., Fujiwara, H., Mann, D. M., Giasson, B., Baba, M., Schmidt, M. L., et al. (1998). Lewy bodies contain altered alpha-synuclein in brains of many familial Alzheimer’s disease patients with mutations in presenilin and amyloid precursor protein genes. American Journal of Pathology, 153(5), 1365–1370. https://doi.org/10.1016/s0002-9440(10)65722-7.
Liu, G., Li, F., Zhang, S., Jiang, Y., Ma, G., Shang, H., et al. (2014a). Analyzing large-scale samples confirms the association between the ABCA7 rs3764650 polymorphism and Alzheimer’s disease susceptibility. Molecular Neurobiology, 50(3), 757–764. https://doi.org/10.1007/s12035-014-8670-4.
Liu, G., Wang, H., Liu, J., Li, J., Li, H., Ma, G., et al. (2014b). The CLU gene rs11136000 variant is significantly associated with Alzheimer’s disease in Caucasian and Asian populations. NeuroMolecular Medicine, 16(1), 52–60. https://doi.org/10.1007/s12017-013-8250-1.
Liu, L., Zhang, K., Sandoval, H., Yamamoto, S., Jaiswal, M., Sanz, E., et al. (2015). Glial lipid droplets and ROS induced by mitochondrial defects promote neurodegeneration. Cell, 160(1–2), 177–190. https://doi.org/10.1016/j.cell.2014.12.019.
Liu, L., MacKenzie, K. R., Putluri, N., Maletic-Savatic, M., & Bellen, H. J. (2017). The glia-neuron lactate shuttle and elevated ROS promote lipid synthesis in neurons and lipid droplet accumulation in glia via APOE/D. Cell Metabolism, 26(5), 719–737 e716. https://doi.org/10.1016/j.cmet.2017.08.024.
Liu, P. P., Xie, Y., Meng, X. Y., & Kang, J. S. (2019). History and progress of hypotheses and clinical trials for Alzheimer’s disease. Signal Transduction and Targeted Therapy, 4(1), 29. https://doi.org/10.1038/s41392-019-0063-8.
Lynch, J. R., Tang, W., Wang, H., Vitek, M. P., Bennett, E. R., Sullivan, P. M., et al. (2003). APOE genotype and an ApoE-mimetic peptide modify the systemic and central nervous system inflammatory response. Journal of Biological Chemistry, 278(49), 48529–48533. https://doi.org/10.1074/jbc.M306923200.
Mann, D. M., Yates, P. O., & Stamp, J. E. (1978). The relationship between lipofuscin pigment and ageing in the human nervous system. Journal of the Neurological Sciences, 37(1–2), 83–93. https://doi.org/10.1016/0022-510x(78)90229-0.
Marchi, C., Adorni, M. P., Caffarra, P., Ronda, N., Spallazzi, M., Barocco, F., et al. (2019). ABCA1- and ABCG1-mediated cholesterol efflux capacity of cerebrospinal fluid is impaired in Alzheimer’s disease. Journal of Lipid Research, 60(8), 1449–1456. https://doi.org/10.1194/jlr.P091033.
Marian, O. C., Tran, C., & Don, A. S. (2020). Chapter 23—Altered lipid metabolic homeostasis in the pathogenesis of Alzheimer’s disease. In J. M. Ntambi (Ed.), Lipid signaling and metabolism (pp. 469–504). London, UK: Academic Press.
Marquer, C., Laine, J., Dauphinot, L., Hanbouch, L., Lemercier-Neuillet, C., Pierrot, N., et al. (2014). Increasing membrane cholesterol of neurons in culture recapitulates Alzheimer’s disease early phenotypes. Molecular Neurodegeneration. https://doi.org/10.1186/1750-1326-9-60.
Marschallinger, J., Iram, T., Zardeneta, M., Lee, S. E., Lehallier, B., Haney, M. S., et al. (2020). Lipid-droplet-accumulating microglia represent a dysfunctional and proinflammatory state in the aging brain. Nature Neuroscience, 23(2), 194–208. https://doi.org/10.1038/s41593-019-0566-1.
Mata, I. F., Leverenz, J. B., Weintraub, D., Trojanowski, J. Q., Chen-Plotkin, A., Van Deerlin, V. M., et al. (2016). GBA variants are associated with a distinct pattern of cognitive deficits in Parkinson’s disease. Movement Disorders, 31(1), 95–102. https://doi.org/10.1002/mds.26359.
Matsuda, J. (2008). Sphingolipid activator proteins. In N. Taniguchi, A. Suzuki, Y. Ito, H. Narimatsu, T. Kawasaki, & S. Hase (Eds.), Experimental glycoscience: Glycobiology (pp. 125–129). Tokyo: Springer.
Mattson, M. P., Fu, W., Waeg, G., & Uchida, K. (1997). 4-Hydroxynonenal, a product of lipid peroxidation, inhibits dephosphorylation of the microtubule-associated protein tau. NeuroReport, 8(9–10), 2275–2281. https://doi.org/10.1097/00001756-199707070-00036.
Mauch, D. H., Nägler, K., Schumacher, S., Göritz, C., Müller, E. C., Otto, A., et al. (2001). CNS synaptogenesis promoted by glia-derived cholesterol. Science (New York, N.Y.), 294(5545), 1354–1357. https://doi.org/10.1126/science.294.5545.1354.
Mazzulli, J. R., Xu, Y. H., Sun, Y., Knight, A. L., McLean, P. J., Caldwell, G. A., et al. (2011). Gaucher disease glucocerebrosidase and alpha-synuclein form a bidirectional pathogenic loop in synucleinopathies. Cell, 146(1), 37–52. https://doi.org/10.1016/j.cell.2011.06.001.
Michikawa, M., Fan, Q. W., Isobe, I., & Yanagisawa, K. (2000). Apolipoprotein E exhibits isoform-specific promotion of lipid efflux from astrocytes and neurons in culture. Journal of Neurochemistry, 74(3), 1008–1016. https://doi.org/10.1046/j.1471-4159.2000.0741008.x.
Minagawa, H., Gong, J.-S., Jung, C.-G., Watanabe, A., Lund-Katz, S., Phillips, M. C., et al. (2009). Mechanism underlying apolipoprotein E (ApoE) isoform-dependent lipid efflux from neural cells in culture. Journal of Neuroscience Research, 87(11), 2498–2508. https://doi.org/10.1002/jnr.22073.
Miron, V. E., Boyd, A., Zhao, J.-W., Yuen, T. J., Ruckh, J. M., Shadrach, J. L., et al. (2013). M2 microglia and macrophages drive oligodendrocyte differentiation during CNS remyelination. Nature Neuroscience, 16(9), 1211–1218. https://doi.org/10.1038/nn.3469.
Mitroi, D. N., Pereyra-Gómez, G., Soto-Huelin, B., Senovilla, F., Kobayashi, T., Esteban, J. A., et al. (2019). NPC1 enables cholesterol mobilization during long-term potentiation that can be restored in Niemann–Pick disease type C by CYP46A1 activation. EMBO Reports, 20(11), e48143. https://doi.org/10.15252/embr.201948143.
Morel, E., Chamoun, Z., Lasiecka, Z. M., Chan, R. B., Williamson, R. L., Vetanovetz, C., et al. (2013). Phosphatidylinositol-3-phosphate regulates sorting and processing of amyloid precursor protein through the endosomal system. Nature Communications, 4, 2250. https://doi.org/10.1038/ncomms3250.
Moreno-Garcia, A., Kun, A., Calero, O., Medina, M., & Calero, M. (2018). An overview of the role of lipofuscin in age-related neurodegeneration. Frontiers in Neuroscience, 12, 464. https://doi.org/10.3389/fnins.2018.00464.
Morrow, J. A., Hatters, D. M., Lu, B., Hochtl, P., Oberg, K. A., Rupp, B., et al. (2002). Apolipoprotein E4 forms a molten globule. A potential basis for its association with disease. Journal of Biological Chemistry, 277(52), 50380–50385. https://doi.org/10.1074/jbc.M204898200.
Mueller, C., Ballard, C., Corbett, A., & Aarsland, D. (2017). The prognosis of dementia with Lewy bodies. The Lancet Neurology, 16(5), 390–398. https://doi.org/10.1016/S1474-4422(17)30074-1.
Murphy, K. E., Gysbers, A. M., Abbott, S. K., Tayebi, N., Kim, W. S., Sidransky, E., et al. (2014). Reduced glucocerebrosidase is associated with increased alpha-synuclein in sporadic Parkinson’s disease. Brain, 137(Pt 3), 834–848. https://doi.org/10.1093/brain/awt367.
Nalls, M. A., Duran, R., Lopez, G., Kurzawa-Akanbi, M., McKeith, I. G., Chinnery, P. F., et al. (2013). A multicenter study of glucocerebrosidase mutations in dementia with Lewy bodies. JAMA Neurology, 70(6), 727–735. https://doi.org/10.1001/jamaneurol.2013.1925.
Nalls, M. A., Pankratz, N., Lill, C. M., Do, C. B., Hernandez, D. G., Saad, M., et al. (2014). Large-scale meta-analysis of genome-wide association data identifies six new risk loci for Parkinson’s disease. Nature Genetics, 46(9), 989–993. https://doi.org/10.1038/ng.3043.
Neudorfer, O., Giladi, N., Elstein, D., Abrahamov, A., Turezkite, T., Aghai, E., et al. (1996). Occurrence of Parkinson’s syndrome in type I Gaucher disease. QJM, 89(9), 691–694. https://doi.org/10.1093/qjmed/89.9.691.
Neumann, J., Bras, J., Deas, E., O’Sullivan, S. S., Parkkinen, L., Lachmann, R. H., et al. (2009a). Glucocerebrosidase mutations in clinical and pathologically proven Parkinson’s disease. Brain, 132(Pt 7), 1783–1794. https://doi.org/10.1093/brain/awp044.
Neumann, M., Rademakers, R., Roeber, S., Baker, M., Kretzschmar, H. A., & Mackenzie, I. R. (2009b). A new subtype of frontotemporal lobar degeneration with FUS pathology. Brain, 132(Pt 11), 2922–2931. https://doi.org/10.1093/brain/awp214.
Newton, J., Milstien, S., & Spiegel, S. (2018). Niemann-Pick type C disease: The atypical sphingolipidosis. Advances in Biological Regulation, 70, 82–88. https://doi.org/10.1016/j.jbior.2018.08.001.
Nilsson, O., & Svennerholm, L. (1982). Accumulation of glucosylceramide and glucosylsphingosine (psychosine) in cerebrum and cerebellum in infantile and juvenile Gaucher disease. Journal of Neurochemistry, 39(3), 709–718.
Nixon, R. A. (2017). Amyloid precursor protein and endosomal–lysosomal dysfunction in Alzheimer’s disease: Inseparable partners in a multifactorial disease. The FASEB Journal, 31(7), 2729–2743. https://doi.org/10.1096/fj.201700359.
Nixon, R. A., Wegiel, J., Kumar, A., Yu, W. H., Peterhoff, C., Cataldo, A., et al. (2005). Extensive involvement of autophagy in Alzheimer disease: An immuno-electron microscopy study. Journal of Neuropathology and Experimental Neurology, 64(2), 113–122. https://doi.org/10.1093/jnen/64.2.113.
Nordestgaard, L. T., Tybjærg-Hansen, A., Nordestgaard, B. G., & Frikke-Schmidt, R. (2015). Loss-of-function mutation in ABCA1 and risk of Alzheimer’s disease and cerebrovascular disease. Alzheimer’s & Dementia: The Journal of the Alzheimer’s Association, 11(12), 1430–1438. https://doi.org/10.1016/j.jalz.2015.04.006.
Nugent, A. A., Lin, K., Lengerich, B. V., Lianoglou, S., Przybyla, L., Davis, S. S., et al. (2020). TREM2 regulates microglial cholesterol metabolism upon chronic phagocytic challenge. Neuron, 105(5), 837–854.e839. https://doi.org/10.1016/j.neuron.2019.12.007.
Nuriel, T., Peng, K. Y., Ashok, A., Dillman, A. A., Figueroa, H. Y., Apuzzo, J., et al. (2017). The endosomal–lysosomal pathway is dysregulated by APOE4 expression in vivo. Frontiers in Neuroscience, 11, 702. https://doi.org/10.3389/fnins.2017.00702.
Olney, N. T., Spina, S., & Miller, B. L. (2017). Frontotemporal dementia. Neurologic Clinics, 35(2), 339–374. https://doi.org/10.1016/j.ncl.2017.01.008.
Ophir, G., Amariglio, N., Jacob-Hirsch, J., Elkon, R., Rechavi, G., & Michaelson, D. M. (2005). Apolipoprotein E4 enhances brain inflammation by modulation of the NF-κB signaling cascade. Neurobiology of Disease, 20(3), 709–718. https://doi.org/10.1016/j.nbd.2005.05.002.
Orme, T., Guerreiro, R., & Bras, J. (2018). The genetics of dementia with Lewy bodies: Current understanding and future directions. Current Neurology and Neuroscience Reports, 18(10), 67. https://doi.org/10.1007/s11910-018-0874-y.
Park, H. K., & Chung, S. J. (2013). New perspective on parkinsonism in frontotemporal lobar degeneration. Journal of Movement Disorders, 6(1), 1–8. https://doi.org/10.14802/jmd.13001.
Parkkinen, L., Pirttila, T., & Alafuzoff, I. (2008). Applicability of current staging/categorization of alpha-synuclein pathology and their clinical relevance. Acta Neuropathologica, 115(4), 399–407. https://doi.org/10.1007/s00401-008-0346-6.
Pimenova, A. A., Raj, T., & Goate, A. M. (2018). Untangling genetic risk for Alzheimer’s disease. Biological Psychiatry, 83(4), 300–310. https://doi.org/10.1016/j.biopsych.2017.05.014.
Pitas, R. E., Boyles, J. K., Lee, S. H., Hui, D., & Weisgraber, K. H. (1987). Lipoproteins and their receptors in the central nervous system. Characterization of the lipoproteins in cerebrospinal fluid and identification of apolipoprotein B,E(LDL) receptors in the brain. The Journal of Biological Chemistry, 262(29), 14352–14360.
Platt, F. M., d’Azzo, A., Davidson, B. L., Neufeld, E. F., & Tifft, C. J. (2018). Lysosomal storage diseases. Nature Reviews Disease Primers, 4(1), 27. https://doi.org/10.1038/s41572-018-0025-4.
Poliani, P. L., Wang, Y., Fontana, E., Robinette, M. L., Yamanishi, Y., Gilfillan, S., et al. (2015). TREM2 sustains microglial expansion during aging and response to demyelination. The Journal of Clinical Investigation, 125(5), 2161–2170. https://doi.org/10.1172/JCI77983.
Prasad, H., & Rao, R. (2018). Amyloid clearance defect in ApoE4 astrocytes is reversed by epigenetic correction of endosomal pH. Proceedings of the National Academy of Sciences, 115(28), E6640–E6649. https://doi.org/10.1073/pnas.1801612115.
Price, J. L., McKeel, D. W., Jr., Buckles, V. D., Roe, C. M., Xiong, C., Grundman, M., et al. (2009). Neuropathology of nondemented aging: Presumptive evidence for preclinical Alzheimer disease. Neurobiology of Aging, 30(7), 1026–1036. https://doi.org/10.1016/j.neurobiolaging.2009.04.002.
Puglielli, L., Konopka, G., Pack-Chung, E., Ingano, L. A. M., Berezovska, O., Hyman, B. T., et al. (2001). Acyl-coenzyme A: Cholesterol acyltransferase modulates the generation of the amyloid β-peptide. Nature Cell Biology, 3(10), 905–912. https://doi.org/10.1038/ncb1001-905.
Quadri, M., Mandemakers, W., Grochowska, M. M., Masius, R., Geut, H., Fabrizio, E., et al. (2018). LRP10 genetic variants in familial Parkinson’s disease and dementia with Lewy bodies: A genome-wide linkage and sequencing study. The Lancet Neurology, 17(7), 597–608. https://doi.org/10.1016/S1474-4422(18)30179-0.
Rademakers, R., Eriksen, J. L., Baker, M., Robinson, T., Ahmed, Z., Lincoln, S. J., et al. (2008). Common variation in the miR-659 binding-site of GRN is a major risk factor for TDP43-positive frontotemporal dementia. Human Molecular Genetics, 17(23), 3631–3642. https://doi.org/10.1093/hmg/ddn257.
Ratnavalli, E., Brayne, C., Dawson, K., & Hodges, J. R. (2002). The prevalence of frontotemporal dementia. Neurology, 58(11), 1615–1621. https://doi.org/10.1212/wnl.58.11.1615.
Rawat, V., Wang, S., Sima, J., Bar, R., Liraz, O., Gundimeda, U., et al. (2019). ApoE4 alters ABCA1 membrane trafficking in astrocytes. The Journal of Neuroscience: The Official Journal of the Society for Neuroscience, 39(48), 9611–9622. https://doi.org/10.1523/JNEUROSCI.1400-19.2019.
Reale, M., Kamal, M. A., Velluto, L., Gambi, D., Di Nicola, M., & Greig, N. H. (2012). Relationship between inflammatory mediators, Aβ levels and ApoE genotype in Alzheimer disease. Current Alzheimer Research, 9(4), 447–457. https://doi.org/10.2174/156720512800492549.
Reas, E. T., Laughlin, G. A., Bergstrom, J., Kritz-Silverstein, D., Barrett-Connor, E., & McEvoy, L. K. (2019). Effects of APOE on cognitive aging in community-dwelling older adults. Neuropsychology, 33(3), 406–416. https://doi.org/10.1037/neu0000501.
Reczek, D., Schwake, M., Schroder, J., Hughes, H., Blanz, J., Jin, X., et al. (2007). LIMP-2 is a receptor for lysosomal mannose-6-phosphate-independent targeting of beta-glucocerebrosidase. Cell, 131(4), 770–783. https://doi.org/10.1016/j.cell.2007.10.018.
Reiman, E. M., Arboleda-Velasquez, J. F., Quiroz, Y. T., Huentelman, M. J., Beach, T. G., Caselli, R. J., et al. (2020). Exceptionally low likelihood of Alzheimer’s dementia in APOE2 homozygotes from a 5,000-person neuropathological study. Nature Communications, 11(1), 667. https://doi.org/10.1038/s41467-019-14279-8.
Reitz, C., Jun, G., Naj, A., Rajbhandary, R., Vardarajan, B. N., Wang, L. S., et al. (2013). Variants in the ATP-binding cassette transporter (ABCA7), apolipoprotein E 4, and the risk of late-onset Alzheimer disease in African Americans. JAMA, 309(14), 1483–1492. https://doi.org/10.1001/jama.2013.2973.
Riddell, D. R., Zhou, H., Atchison, K., Warwick, H. K., Atkinson, P. J., Jefferson, J., et al. (2008). Impact of apolipoprotein E (ApoE) polymorphism on brain ApoE levels. The Journal of Neuroscience, 28(45), 11445–11453. https://doi.org/10.1523/JNEUROSCI.1972-08.2008.
Rigante, D., Cipolla, C., Basile, U., Gulli, F., & Savastano, M. C. (2017). Overview of immune abnormalities in lysosomal storage disorders. Immunology Letters, 188, 79–85. https://doi.org/10.1016/j.imlet.2017.07.004.
Robak, L. A., Jansen, I. E., van Rooij, J., Uitterlinden, A. G., Kraaij, R., Jankovic, J., et al. (2017). Excessive burden of lysosomal storage disorder gene variants in Parkinson’s disease. Brain, 140(12), 3191–3203. https://doi.org/10.1093/brain/awx285.
Rocha, E. M., Smith, G. A., Park, E., Cao, H., Brown, E., Hallett, P., et al. (2015a). Progressive decline of glucocerebrosidase in aging and Parkinson’s disease. Annals of Clinical and Translational Neurology, 2(4), 433–438. https://doi.org/10.1002/acn3.177.
Rocha, E. M., Smith, G. A., Park, E., Cao, H., Graham, A. R., Brown, E., et al. (2015b). Sustained systemic glucocerebrosidase inhibition induces brain alpha-synuclein aggregation, microglia and complement C1q activation in mice. Antioxidants & Redox Signaling, 23(6), 550–564. https://doi.org/10.1089/ars.2015.6307.
Rodrigue, K. M., Kennedy, K. M., Devous, M. D., Sr., Rieck, J. R., Hebrank, A. C., Diaz-Arrastia, R., et al. (2012). beta-Amyloid burden in healthy aging: Regional distribution and cognitive consequences. Neurology, 78(6), 387–395. https://doi.org/10.1212/WNL.0b013e318245d295.
Rodríguez, E., Mateo, I., Infante, J., Llorca, J., Berciano, J., & Combarros, O. (2006). Cholesteryl ester transfer protein (CETP) polymorphism modifies the Alzheimer’s disease risk associated with APOE epsilon4 allele. Journal of Neurology, 253(2), 181–185. https://doi.org/10.1007/s00415-005-0945-2.
Rossor, M. N., Fox, N. C., Mummery, C. J., Schott, J. M., & Warren, J. D. (2010). The diagnosis of young-onset dementia. The Lancet Neurology, 9(8), 793–806. https://doi.org/10.1016/s1474-4422(10)70159-9.
Ryan, C. L., Baranowski, D. C., Chitramuthu, B. P., Malik, S., Li, Z., Cao, M., et al. (2009). Progranulin is expressed within motor neurons and promotes neuronal cell survival. BMC Neuroscience, 10, 130. https://doi.org/10.1186/1471-2202-10-130.
Saito, Y., Suzuki, K., Nanba, E., Yamamoto, T., Ohno, K., & Murayama, S. (2002). Niemann-Pick type C disease: Accelerated neurofibrillary tangle formation and amyloid β deposition associated with apolipoprotein E ε4 homozygosity. Annals of Neurology, 52(3), 351–355. https://doi.org/10.1002/ana.10266.
Sakae, N., Liu, C.-C., Shinohara, M., Frisch-Daiello, J., Ma, L., Yamazaki, Y., et al. (2016). ABCA7 deficiency accelerates amyloid-β generation and Alzheimer’s neuronal pathology. The Journal of Neuroscience: The Official Journal of the Society for Neuroscience, 36(13), 3848–3859. https://doi.org/10.1523/JNEUROSCI.3757-15.2016.
Sandhoff, K. (2013). Metabolic and cellular bases of sphingolipidoses. Biochemical Society Transactions, 41(6), 1562–1568. https://doi.org/10.1042/BST20130083.
Sando, S. B., Melquist, S., Cannon, A., Hutton, M. L., Sletvold, O., Saltvedt, I., et al. (2008). APOE ε4 lowers age at onset and is a high risk factor for Alzheimer’s disease; A case control study from central Norway. BMC Neurology, 8(1), 9. https://doi.org/10.1186/1471-2377-8-9.
Sardi, S. P., Clarke, J., Kinnecom, C., Tamsett, T. J., Li, L., Stanek, L. M., et al. (2011). CNS expression of glucocerebrosidase corrects alpha-synuclein pathology and memory in a mouse model of Gaucher-related synucleinopathy. Proceedings of the National Academy of Sciences of the United States of America, 108(29), 12101–12106. https://doi.org/10.1073/pnas.1108197108.
Saunders, A. M., Strittmatter, W. J., Schmechel, D., George-Hyslop, P. H., Pericak-Vance, M. A., Joo, S. H., et al. (1993). Association of apolipoprotein E allele epsilon 4 with late-onset familial and sporadic Alzheimer’s disease. Neurology, 43(8), 1467–1472. https://doi.org/10.1212/wnl.43.8.1467.
Schmitt, S., Castelvetri, L. C., & Simons, M. (2015). Metabolism and functions of lipids in myelin. Biochimica et Biophysica Acta, 1851(8), 999–1005. https://doi.org/10.1016/j.bbalip.2014.12.016.
Schnaar, R. L. (2019). The biology of gangliosides. Advances in Carbohydrate Chemistry and Biochemistry, 76, 113–148. https://doi.org/10.1016/bs.accb.2018.09.002.
Shi, C. H., Tang, B. S., Wang, L., Lv, Z. Y., Wang, J., Luo, L. Z., et al. (2011). PLA2G6 gene mutation in autosomal recessive early-onset parkinsonism in a Chinese cohort. Neurology, 77(1), 75–81. https://doi.org/10.1212/WNL.0b013e318221acd3.
Shibuya, Y., Chang, C. C. Y., Huang, L.-H., Bryleva, E. Y., & Chang, T.-Y. (2014). Inhibiting ACAT1/SOAT1 in microglia stimulates autophagy-mediated lysosomal proteolysis and increases Aβ1-42 clearance. The Journal of Neuroscience: The Official Journal of the Society for Neuroscience, 34(43), 14484–14501. https://doi.org/10.1523/JNEUROSCI.2567-14.2014.
Shibuya, Y., Niu, Z., Bryleva, E. Y., Harris, B. T., Murphy, S. R., Kheirollah, A., et al. (2015). Acyl-coenzyme A:cholesterol acyltransferase 1 blockage enhances autophagy in the neurons of triple transgenic Alzheimer’s disease mouse and reduces human P301L-tau content at the presymptomatic stage. Neurobiology of Aging, 36(7), 2248–2259. https://doi.org/10.1016/j.neurobiolaging.2015.04.002.
Shulman, J. M., Chen, K., Keenan, B. T., Chibnik, L. B., Fleisher, A., Thiyyagura, P., et al. (2013). Genetic susceptibility for Alzheimer disease neuritic plaque pathology. JAMA Neurology, 70(9), 1150–1157. https://doi.org/10.1001/jamaneurol.2013.2815.
Sidransky, E., Nalls, M. A., Aasly, J. O., Aharon-Peretz, J., Annesi, G., Barbosa, E. R., et al. (2009). Multicenter analysis of glucocerebrosidase mutations in Parkinson’s disease. New England Journal of Medicine, 361(17), 1651–1661. https://doi.org/10.1056/NEJMoa0901281.
Sims, R., van der Lee, S. J., Naj, A. C., Bellenguez, C., Badarinarayan, N., Jakobsdottir, J., et al. (2017). Rare coding variants in PLCG2, ABI3, and TREM2 implicate microglial-mediated innate immunity in Alzheimer’s disease. Nature Genetics, 49(9), 1373–1384. https://doi.org/10.1038/ng.3916.
Sina, F., Shojaee, S., Elahi, E., & Paisan-Ruiz, C. (2009). R632W mutation in PLA2G6 segregates with dystonia-parkinsonism in a consanguineous Iranian family. European Journal of Neurology, 16(1), 101–104. https://doi.org/10.1111/j.1468-1331.2008.02356.x.
Siuda, J., Fujioka, S., & Wszolek, Z. K. (2014). Parkinsonian syndrome in familial frontotemporal dementia. Parkinsonism & Related Disorders, 20(9), 957–964. https://doi.org/10.1016/j.parkreldis.2014.06.004.
Sleat, D. E., Wiseman, J. A., El-Banna, M., Price, S. M., Verot, L., Shen, M. M., et al. (2004). Genetic evidence for nonredundant functional cooperativity between NPC1 and NPC2 in lipid transport. Proceedings of the National Academy of Sciences of the United States of America, 101(16), 5886–5891. https://doi.org/10.1073/pnas.0308456101.
Slooter, A. J. C., Cruts, M., Kalmijn, S., Hofman, A., Breteler, M. M. B., Broeckhoven, C. V., et al. (1998). Risk estimates of dementia by apolipoprotein E genotypes from a population-based incidence study: The Rotterdam Study. Archives of Neurology, 55(7), 964–968. https://doi.org/10.1001/archneur.55.7.964.
Smith, K. R., Damiano, J., Franceschetti, S., Carpenter, S., Canafoglia, L., Morbin, M., et al. (2012). Strikingly different clinicopathological phenotypes determined by progranulin-mutation dosage. American Journal of Human Genetics, 90(6), 1102–1107. https://doi.org/10.1016/j.ajhg.2012.04.021.
Song, W., Hooli, B., Mullin, K., Jin, S. C., Cella, M., Ulland, T. K., et al. (2017). Alzheimer’s disease-associated TREM2 variants exhibit either decreased or increased ligand-dependent activation. Alzheimer’s & Dementia, 13(4), 381–387. https://doi.org/10.1016/j.jalz.2016.07.004.
Sreedharan, J., Blair, I. P., Tripathi, V. B., Hu, X., Vance, C., Rogelj, B., et al. (2008). TDP-43 mutations in familial and sporadic amyotrophic lateral sclerosis. Science, 319(5870), 1668–1672. https://doi.org/10.1126/science.1154584.
Stefanatos, R., & Sanz, A. (2018). The role of mitochondrial ROS in the aging brain. FEBS Letters, 592(5), 743–758. https://doi.org/10.1002/1873-3468.12902.
Suzuki, K., Iseki, E., Katsuse, O., Yamaguchi, A., Katsuyama, K., Aoki, I., et al. (2003). Neuronal accumulation of alpha- and beta-synucleins in the brain of a GM2 gangliosidosis mouse model. NeuroReport, 14(4), 551–554. https://doi.org/10.1097/01.wnr.0000061017.47393.dc.
Suzuki, K., Iseki, E., Togo, T., Yamaguchi, A., Katsuse, O., Katsuyama, K., et al. (2007). Neuronal and glial accumulation of alpha- and beta-synucleins in human lipidoses. Acta Neuropathologica, 114(5), 481–489. https://doi.org/10.1007/s00401-007-0264-z.
Tachibana, M., Holm, M.-L., Liu, C.-C., Shinohara, M., Aikawa, T., Oue, H., et al. (2019). APOE4-mediated amyloid-β pathology depends on its neuronal receptor LRP1. The Journal of Clinical Investigation, 129(3), 1272–1277. https://doi.org/10.1172/JCI124853.
Taguchi, Y. V., Liu, J., Ruan, J., Pacheco, J., Zhang, X., Abbasi, J., et al. (2017). Glucosylsphingosine promotes alpha-synuclein pathology in mutant GBA-associated Parkinson’s disease. The Journal of Neuroscience, 37(40), 9617–9631. https://doi.org/10.1523/JNEUROSCI.1525-17.2017.
Takasugi, N., Sasaki, T., Suzuki, K., Osawa, S., Isshiki, H., Hori, Y., et al. (2011). BACE1 activity is modulated by cell-associated sphingosine-1-phosphate. The Journal of Neuroscience: The Official Journal of the Society for Neuroscience, 31(18), 6850–6857. https://doi.org/10.1523/JNEUROSCI.6467-10.2011.
Tamargo, R. J., Velayati, A., Goldin, E., & Sidransky, E. (2012). The role of saposin C in Gaucher disease. Molecular Genetics and Metabolism, 106(3), 257–263. https://doi.org/10.1016/j.ymgme.2012.04.024.
Tanaka, Y., Suzuki, G., Matsuwaki, T., Hosokawa, M., Serrano, G., Beach, T. G., et al. (2017). Progranulin regulates lysosomal function and biogenesis through acidification of lysosomes. Human Molecular Genetics, 26(5), 969–988. https://doi.org/10.1093/hmg/ddx011.
Tayebi, N., Walker, J., Stubblefield, B., Orvisky, E., LaMarca, M. E., Wong, K., et al. (2003). Gaucher disease with parkinsonian manifestations: Does glucocerebrosidase deficiency contribute to a vulnerability to parkinsonism? Molecular Genetics and Metabolism, 79(2), 104–109.
Tayebi, N., Parisiadou, L., Berhe, B., Gonzalez, A. N., Serra-Vinardell, J., Tamargo, R. J., et al. (2017). Glucocerebrosidase haploinsufficiency in A53T alpha-synuclein mice impacts disease onset and course. Molecular Genetics and Metabolism, 122(4), 198–208. https://doi.org/10.1016/j.ymgme.2017.11.001.
Tome, S. O., Vandenberghe, R., Ospitalieri, S., Van Schoor, E., Tousseyn, T., Otto, M., et al. (2020). Distinct molecular patterns of TDP-43 pathology in Alzheimer’s disease: Relationship with clinical phenotypes. Acta Neuropathologica Communications, 8(1), 61. https://doi.org/10.1186/s40478-020-00934-5.
Tsuang, D., Leverenz, J. B., Lopez, O. L., Hamilton, R. L., Bennett, D. A., Schneider, J. A., et al. (2013). APOE epsilon4 increases risk for dementia in pure synucleinopathies. JAMA Neurology, 70(2), 223–228. https://doi.org/10.1001/jamaneurol.2013.600.
Valdez, C., Wong, Y. C., Schwake, M., Bu, G., Wszolek, Z. K., & Krainc, D. (2017). Progranulin-mediated deficiency of cathepsin D results in FTD and NCL-like phenotypes in neurons derived from FTD patients. Human Molecular Genetics, 26(24), 4861–4872. https://doi.org/10.1093/hmg/ddx364.
Valdez, C., Ysselstein, D., Young, T. J., Zheng, J., & Krainc, D. (2019). Progranulin mutations result in impaired processing of prosaposin and reduced glucocerebrosidase activity. Human Molecular Genetics. https://doi.org/10.1093/hmg/ddz229.
Van Acker, Z. P., Bretou, M., & Annaert, W. (2019). Endo-lysosomal dysregulations and late-onset Alzheimer’s disease: Impact of genetic risk factors. Molecular Neurodegeneration, 14(1), 20. https://doi.org/10.1186/s13024-019-0323-7.
Van Damme, P., Van Hoecke, A., Lambrechts, D., Vanacker, P., Bogaert, E., van Swieten, J., et al. (2008). Progranulin functions as a neurotrophic factor to regulate neurite outgrowth and enhance neuronal survival. Journal of Cell Biology, 181(1), 37–41. https://doi.org/10.1083/jcb.200712039.
van der Kant, R., Langness, V. F., Herrera, C. M., Williams, D. A., Fong, L. K., Leestemaker, Y., et al. (2019). Cholesterol metabolism is a druggable axis that independently regulates tau and amyloid-β in iPSC-derived Alzheimer’s disease neurons. Cell Stem Cell, 24(3), 363–375.e369. https://doi.org/10.1016/j.stem.2018.12.013.
Vann Jones, S. A., & O’Brien, J. T. (2014). The prevalence and incidence of dementia with Lewy bodies: A systematic review of population and clinical studies. Psychological Medicine, 44(4), 673–683. https://doi.org/10.1017/S0033291713000494.
Vieira, R. T., Caixeta, L., Machado, S., Silva, A. C., Nardi, A. E., Arias-Carrion, O., et al. (2013). Epidemiology of early-onset dementia: A review of the literature. Clinical Practice & Epidemiology in Mental Health, 9, 88–95. https://doi.org/10.2174/1745017901309010088.
Vitek, M. P., Brown, C. M., & Colton, C. A. (2009). APOE genotype-specific differences in the innate immune response. Neurobiology of Aging, 30(9), 1350–1360. https://doi.org/10.1016/j.neurobiolaging.2007.11.014.
Vitner, E. B., Platt, F. M., & Futerman, A. H. (2010). Common and uncommon pathogenic cascades in lysosomal storage diseases. Journal of Biological Chemistry, 285(27), 20423–20427. https://doi.org/10.1074/jbc.R110.134452.
Wahrle, S. E., Jiang, H., Parsadanian, M., Legleiter, J., Han, X., Fryer, J. D., et al. (2004). ABCA1 is required for normal central nervous system ApoE levels and for lipidation of astrocyte-secreted apoE. Journal of Biological Chemistry, 279(39), 40987–40993. https://doi.org/10.1074/jbc.M407963200.
Wahrle, S. E., Jiang, H., Parsadanian, M., Hartman, R. E., Bales, K. R., Paul, S. M., et al. (2005). Deletion of Abca1 increases Abeta deposition in the PDAPP transgenic mouse model of Alzheimer disease. Journal of Biological Chemistry, 280(52), 43236–43242. https://doi.org/10.1074/jbc.M508780200.
Wahrle, S. E., Jiang, H., Parsadanian, M., Kim, J., Li, A., Knoten, A., et al. (2008). Overexpression of ABCA1 reduces amyloid deposition in the PDAPP mouse model of Alzheimer disease. Journal of Clinical Investigation, 118(2), 671–682. https://doi.org/10.1172/JCI33622.
Walker, Z., Possin, K. L., Boeve, B. F., & Aarsland, D. (2015). Lewy body dementias. Lancet, 386(10004), 1683–1697. https://doi.org/10.1016/S0140-6736(15)00462-6.
Wang, Y., Cella, M., Mallinson, K., Ulrich, J. D., Young, K. L., Robinette, M. L., et al. (2015). TREM2 lipid sensing sustains the microglial response in an Alzheimer’s disease model. Cell, 160(6), 1061–1071. https://doi.org/10.1016/j.cell.2015.01.049.
Ward, M. E., Chen, R., Huang, H. Y., Ludwig, C., Telpoukhovskaia, M., Taubes, A., et al. (2017). Individuals with progranulin haploinsufficiency exhibit features of neuronal ceroid lipofuscinosis. Science Translational Medicine, 9(385), eaah5642. https://doi.org/10.1126/scitranslmed.aah5642.
Wils, H., Kleinberger, G., Pereson, S., Janssens, J., Capell, A., Van Dam, D., et al. (2012). Cellular ageing, increased mortality and FTLD-TDP-associated neuropathology in progranulin knockout mice. The Journal of Pathology, 228(1), 67–76. https://doi.org/10.1002/path.4043.
Winner, B., Jappelli, R., Maji, S. K., Desplats, P. A., Boyer, L., Aigner, S., et al. (2011). In vivo demonstration that alpha-synuclein oligomers are toxic. Proceedings of the National Academy of Sciences of the United States of America, 108(10), 4194–4199. https://doi.org/10.1073/pnas.1100976108.
Xian, X., Pohlkamp, T., Durakoglugil, M. S., Wong, C. H., Beck, J. K., Lane-Donovan, C., et al. (2018). Reversal of ApoE4-induced recycling block as a novel prevention approach for Alzheimer’s disease. eLife. https://doi.org/10.7554/eLife.40048.
Xu, Y. H., Sun, Y., Ran, H., Quinn, B., Witte, D., & Grabowski, G. A. (2011). Accumulation and distribution of alpha-synuclein and ubiquitin in the CNS of Gaucher disease mouse models. Molecular Genetics and Metabolism, 102(4), 436–447. https://doi.org/10.1016/j.ymgme.2010.12.014.
Yadav, U. C., & Ramana, K. V. (2013). Regulation of NF-kappaB-induced inflammatory signaling by lipid peroxidation-derived aldehydes. Oxidative Medicine and Cellular Longevity, 2013, 690545. https://doi.org/10.1155/2013/690545.
Yassine, H. N., Feng, Q., Chiang, J., Petrosspour, L. M., Fonteh, A. N., Chui, H. C., et al. (2016). ABCA1-mediated cholesterol efflux capacity to cerebrospinal fluid is reduced in patients with mild cognitive impairment and Alzheimer’s disease. Journal of the American Heart Association, 5(2), e002886. https://doi.org/10.1161/JAHA.115.002886.
Ye, S., Huang, Y., Müllendorff, K., Dong, L., Giedt, G., Meng, E. C., et al. (2005). Apolipoprotein (apo) E4 enhances amyloid beta peptide production in cultured neuronal cells: apoE structure as a potential therapeutic target. Proceedings of the National Academy of Sciences of the United States of America, 102(51), 18700–18705. https://doi.org/10.1073/pnas.0508693102.
Yeh, F. L., Wang, Y., Tom, I., Gonzalez, L. C., & Sheng, M. (2016). TREM2 binds to apolipoproteins, including APOE and CLU/APOJ, and thereby facilitates uptake of amyloid-beta by microglia. Neuron, 91(2), 328–340. https://doi.org/10.1016/j.neuron.2016.06.015.
Yiannopoulou, K. G., & Papageorgiou, S. G. (2020). Current and future treatments in Alzheimer disease: An update. Journal of Central Nervous System Disease, 12, 1179573520907397. https://doi.org/10.1177/1179573520907397.
Yin, F., Dumont, M., Banerjee, R., Ma, Y., Li, H., Lin, M. T., et al. (2010). Behavioral deficits and progressive neuropathology in progranulin-deficient mice: A mouse model of frontotemporal dementia. The FASEB Journal, 24(12), 4639–4647. https://doi.org/10.1096/fj.10-161471.
Yvan-Charvet, L., Ranalletta, M., Wang, N., Han, S., Terasaka, N., Li, R., et al. (2007). Combined deficiency of ABCA1 and ABCG1 promotes foam cell accumulation and accelerates atherosclerosis in mice. Journal of Clinical Investigation, 117(12), 3900–3908. https://doi.org/10.1172/JCI33372.
Yvan-Charvet, L., Welch, C., Pagler, T. A., Ranalletta, M., Lamkanfi, M., Han, S., et al. (2008). Increased inflammatory gene expression in ABC transporter-deficient macrophages: Free cholesterol accumulation, increased signaling via toll-like receptors, and neutrophil infiltration of atherosclerotic lesions. Circulation, 118(18), 1837–1847. https://doi.org/10.1161/CIRCULATIONAHA.108.793869.
Zhang, Y., Chen, K., Sloan, S. A., Bennett, M. L., Scholze, A. R., O’Keeffe, S., et al. (2014). An RNA-Sequencing transcriptome and splicing database of glia, neurons, and vascular cells of the cerebral cortex. The Journal of Neuroscience, 34(36), 11929–11947. https://doi.org/10.1523/JNEUROSCI.1860-14.2014.
Zhang, S., Li, X., Ma, G., Jiang, Y., Liao, M., Feng, R., et al. (2016). CLU rs9331888 polymorphism contributes to Alzheimer’s disease susceptibility in Caucasian but not East Asian populations. Molecular Neurobiology, 53(3), 1446–1451. https://doi.org/10.1007/s12035-015-9098-1.
Zhao, N., Liu, C.-C., Van Ingelgom, A. J., Martens, Y. A., Linares, C., Knight, J. A., et al. (2017). Apolipoprotein E4 impairs neuronal insulin signaling by trapping insulin receptor in the endosomes. Neuron, 96(1), 115–129.e115. https://doi.org/10.1016/j.neuron.2017.09.003.
Zhao, Y., Wu, X., Li, X., Jiang, L.-L., Gui, X., Liu, Y., et al. (2018). TREM2 is a receptor for β-amyloid that mediates microglial function. Neuron, 97(5), 1023–1031.e1027. https://doi.org/10.1016/j.neuron.2018.01.031.
Zhao, N., Attrebi, O. N., Ren, Y., Qiao, W., Sonustun, B., Martens, Y. A., et al. (2020). APOE4 exacerbates alpha-synuclein pathology and related toxicity independent of amyloid. Science Translational Medicine, 12(529), eaay1809. https://doi.org/10.1126/scitranslmed.aay1809.
Zhou, X., Sun, L., Bastos de Oliveira, F., Qi, X., Brown, W. J., Smolka, M. B., et al. (2015). Prosaposin facilitates sortilin-independent lysosomal trafficking of progranulin. Journal of Cell Biology, 210(6), 991–1002. https://doi.org/10.1083/jcb.201502029.
Zhou, X., Sun, L., Bracko, O., Choi, J. W., Jia, Y., Nana, A. L., et al. (2017). Impaired prosaposin lysosomal trafficking in frontotemporal lobar degeneration due to progranulin mutations. Nature Communications, 8, 15277. https://doi.org/10.1038/ncomms15277.
Zhu, J., Nathan, C., Jin, W., Sim, D., Ashcroft, G. S., Wahl, S. M., et al. (2002). Conversion of proepithelin to epithelins: Roles of SLPI and elastase in host defense and wound repair. Cell, 111(6), 867–878. https://doi.org/10.1016/s0092-8674(02)01141-8.
Zhu, L., Zhong, M., Elder, G. A., Sano, M., Holtzman, D. M., Gandy, S., et al. (2015). Phospholipid dysregulation contributes to ApoE4-associated cognitive deficits in Alzheimer’s disease pathogenesis. Proceedings of the National Academy of Sciences of the United States of America, 112(38), 11965–11970. https://doi.org/10.1073/pnas.1510011112.
Funding
This study was funded by Project Grants APP1100626 and APP1163429 from the National Health and Medical Research Council of Australia (A.S.D.). J.Y.L. and O.C.M. are supported by Research Training Program scholarships (Department of Education, Skills and Employment, Australia).
Author information
Authors and Affiliations
Contributions
All authors performed the literature searches and wrote sections of the manuscript. JYL and ASD drafted and critically reviewed the complete version.
Corresponding author
Ethics declarations
Conflict of interest
The authors declare that they have no conflict of interest.
Ethical Approval
Not applicable.
Informed Consent
Not applicable.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Lee, J.Y., Marian, O.C. & Don, A.S. Defective Lysosomal Lipid Catabolism as a Common Pathogenic Mechanism for Dementia. Neuromol Med 23, 1–24 (2021). https://doi.org/10.1007/s12017-021-08644-4
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12017-021-08644-4